Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01906307 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome
A Phase 1 study, sponsored by La Jolla Pharmaceutical Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01906307: Clinical Trial Phase 1 study, sponsored by La Jolla Pharmaceutical Company.
NCT01906307 is a Phase 1 study that was terminated before completion, run by La Jolla Pharmaceutical Company. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01906307, a Phase 1 study, was terminated before completion, sponsored by La Jolla Pharmaceutical Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Hepatorenal syndrome (HRS) is a life-threatening condition marked by rapid decline in kidney function in patients with liver cirrhosis or fulminant liver failure. Vasodilation in the gastrointestinal region is largely thought to contribute to the disease. LJPC-501 is a vasoconstrictor that may restore proper circulation and kidney function in patients with HRS.
Interventions
- DRUG LJPC-501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Why NCT01906307 stopped before completion
NCT01906307 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which LJPC-501 is the first listed.
NCT01906307 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01906307 about?
NCT01906307 is a clinical study titled "A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome". Hepatorenal syndrome (HRS) is a life-threatening condition marked by rapid decline in kidney function in patients with liver cirrhosis or fulminant liver failure. Vasodilation in the gastrointestinal region is largely thought to contribute to the disease. LJPC-501 is a vasoconstrictor that may resto...
What is the current status of trial NCT01906307?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-03. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01906307?
The interventions under investigation include: LJPC-501 (DRUG).
Who is sponsoring clinical trial NCT01906307?
This trial is sponsored by La Jolla Pharmaceutical Company, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01906307's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia